JP2024505128A5 - - Google Patents
Info
- Publication number
- JP2024505128A5 JP2024505128A5 JP2023540516A JP2023540516A JP2024505128A5 JP 2024505128 A5 JP2024505128 A5 JP 2024505128A5 JP 2023540516 A JP2023540516 A JP 2023540516A JP 2023540516 A JP2023540516 A JP 2023540516A JP 2024505128 A5 JP2024505128 A5 JP 2024505128A5
- Authority
- JP
- Japan
- Prior art keywords
- mass
- volume
- cancer
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020141601 | 2020-12-30 | ||
| CNPCT/CN2020/141601 | 2020-12-30 | ||
| PCT/CN2021/092485 WO2022142053A1 (en) | 2020-12-30 | 2021-05-08 | Formulations of anti-cd73 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505128A JP2024505128A (ja) | 2024-02-05 |
| JP2024505128A5 true JP2024505128A5 (cg-RX-API-DMAC10.html) | 2024-05-17 |
Family
ID=82258959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540516A Pending JP2024505128A (ja) | 2020-12-30 | 2021-05-08 | 抗ｃｄ７３抗体の製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240101698A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4271410A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024505128A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230127292A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116615458A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021415180A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3203441A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022142053A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025021098A1 (zh) * | 2023-07-24 | 2025-01-30 | 石药集团巨石生物制药有限公司 | 重组人源化抗cd73单克隆抗体的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2578131A1 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
| WO2010056804A1 (en) * | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| CN102512384B (zh) * | 2011-12-29 | 2014-11-26 | 嘉和生物药业有限公司 | 一种冻干剂型蛋白组合物及其制备方法 |
| CN108025072A (zh) * | 2015-09-22 | 2018-05-11 | 辉瑞公司 | 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| US20210054079A1 (en) * | 2018-04-25 | 2021-02-25 | Medimmune Limited | Formulations of human anti-pd-li antibodies |
| CN112041348B (zh) * | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
| SG11202105152YA (en) * | 2018-11-30 | 2021-06-29 | Abl Bio Inc | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
-
2021
- 2021-05-08 JP JP2023540516A patent/JP2024505128A/ja active Pending
- 2021-05-08 CA CA3203441A patent/CA3203441A1/en active Pending
- 2021-05-08 AU AU2021415180A patent/AU2021415180A1/en active Pending
- 2021-05-08 KR KR1020237025806A patent/KR20230127292A/ko active Pending
- 2021-05-08 WO PCT/CN2021/092485 patent/WO2022142053A1/en not_active Ceased
- 2021-05-08 CN CN202180079028.7A patent/CN116615458A/zh active Pending
- 2021-05-08 US US18/270,472 patent/US20240101698A1/en active Pending
- 2021-05-08 EP EP21912814.7A patent/EP4271410A4/en active Pending